Kura Oncology (NASDAQ:KURA) Given Market Outperform Rating at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a report published on Wednesday,Benzinga reports. The firm currently has a $28.00 price objective on the stock.

Other research analysts have also recently issued research reports about the company. UBS Group decreased their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Wall Street Zen downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a report on Tuesday, April 8th. Barclays lowered their price objective on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating for the company in a research report on Friday, May 2nd. Finally, Mizuho cut their target price on shares of Kura Oncology from $32.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, May 19th. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.50.

Kura Oncology Stock Performance

NASDAQ KURA opened at $6.73 on Wednesday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $582.65 million, a P/E ratio of -2.85 and a beta of 0.50. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $23.48. The firm has a 50-day moving average price of $6.07 and a two-hundred day moving average price of $7.69.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million. Analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently added to or reduced their stakes in KURA. Virtus ETF Advisers LLC raised its holdings in shares of Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock valued at $64,000 after buying an additional 3,061 shares in the last quarter. State of Wyoming bought a new position in Kura Oncology during the first quarter valued at approximately $48,000. Harbor Advisors LLC purchased a new position in shares of Kura Oncology during the fourth quarter worth approximately $87,000. Pallas Capital Advisors LLC bought a new stake in shares of Kura Oncology in the 1st quarter worth approximately $66,000. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Kura Oncology in the 4th quarter valued at $90,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.